MYDA Advisors’s Crescent Biopharma CBIO Stock Holding History

MYDA Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-150	Closed	-$252K	–	142
2017 Q4	$252K	Buy	+150	New	+$198K	0.11%	127

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MYDA Advisors's CBIO Position: Q1 2018 in Review

MYDA Advisors sold out of Crescent Biopharma (CBIO) in Q1 2018, closing a stake of 150 shares — an estimated $252K sold.

MYDA Advisors first reported a position in CBIO in Q4 2017 and held it in 1 quarter. The position peaked at $252K in Q4 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q1 2018.

MYDA Advisors reported no remaining Crescent Biopharma position as of Q1 2018 after selling out during the quarter.
MYDA Advisors sold 150 Crescent Biopharma shares in Q1 2018, an estimated $252K.
MYDA Advisors first reported a position in Crescent Biopharma in Q4 2017 and held it in 1 quarter.
MYDA Advisors's Crescent Biopharma position peaked at $252K in Q4 2017.
84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2018.

Based on MYDA Advisors's 13F filing for Q1 2018, filed 10 May 2018.